Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Inovio Pharmaceuticals stock in Canada | $7.57

Own Inovio Pharmaceuticals shares in just a few minutes.

Inovio Pharmaceuticals Inc
NASDAQ: INO - USD
BIOTECHNOLOGY
$7.75
+ $0.18 ( + 2.38%)

Inovio Pharmaceuticals is a biotechnology business based in the US. Inovio Pharmaceuticals stocks (INO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.7 – a decrease of 9.88% over the previous week. Inovio Pharmaceuticals employs 262 staff and has a trailing 12-month revenue of around $6.5 million.

How to buy Inovio Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: INO in this case.
  5. Research Inovio Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your Inovio Pharmaceuticals stocks. It's that simple.

Is it a good time to buy Inovio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Inovio Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Inovio Pharmaceuticals's stock price has had significant positive movement.

Its last market close was $7.57, which is 50.53% up on its pre-crash value of $3.745 and 141.08% up on the lowest point reached during the March crash when the stocks fell as low as $3.14.

If you had bought $1,000 worth of Inovio Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $1,693.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,936.03.

Inovio Pharmaceuticals stock price

Use our graph to track the performance of INO stocks over time.

Inovio Pharmaceuticals stocks at a glance

Information last updated 2021-09-10.
Latest market close$7.57
52-week range$5.81 - $19
50-day moving average $8.5986
200-day moving average $8.6266
Wall St. target price$13.33
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.754

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.

An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Inovio Pharmaceuticals price performance over time

Historical closes compared with the last close of $7.57

1 week (2021-09-09) -9.88%
1 month (2021-08-16) -9.12%
3 months (2021-06-16) -11.67%
6 months (2021-03-16) -27.70%
1 year (2020-09-16) -59.13%
2 years (2019-09-16) 181.41%
3 years (2018-09-14) 49.90%
5 years (2016-09-16) -18.07%

Inovio Pharmaceuticals financials

Revenue TTM USD$6.5 million
Gross profit TTM USD$-86,834,216
Return on assets TTM -24.33%
Return on equity TTM -40.79%
Profit margin 0%
Book value $2.42
Market capitalisation USD$1.7 billion

TTM: trailing 12 months

How to short and sell Inovio Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "INO.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 42.6 million Inovio Pharmaceuticals stocks held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 1.9% down from 43.4 million last month.

There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals stocks can be evaluated.

Inovio Pharmaceuticals's "short interest ratio" (SIR)

Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals stocks currently shorted divided by the average quantity of Inovio Pharmaceuticals stocks traded daily (recently around 4.9 million). Inovio Pharmaceuticals's SIR currently stands at 8.63. In other words for every 100,000 Inovio Pharmaceuticals stocks traded daily on the market, roughly 8630 stocks are currently held short.

However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals stocks, or, against the total number of tradable Inovio Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.2% of the outstanding stocks (for every 100,000 Inovio Pharmaceuticals stocks in existence, roughly 200 stocks are currently held short) or 0.2057% of the tradable stocks (for every 100,000 tradable Inovio Pharmaceuticals stocks, roughly 206 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Inovio Pharmaceuticals.

Find out more about how you can short Inovio Pharmaceuticals stock.

Inovio Pharmaceuticals stock dividends

We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Inovio Pharmaceuticals stocks ever split?

Inovio Pharmaceuticals stocks were split on a 1:4 basis on 6 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals stocks – just the quantity. However, indirectly, the new 300% higher stock price could have impacted the market appetite for Inovio Pharmaceuticals stocks which in turn could have impacted Inovio Pharmaceuticals's stock price.

Inovio Pharmaceuticals stock price volatility

Over the last 12 months, Inovio Pharmaceuticals's stocks have ranged in value from as little as $5.81 up to $19. A popular way to gauge a stock's volatility is its "beta".

INO.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.6206. This would suggest that Inovio Pharmaceuticals's stocks are less volatile than average (for this exchange).

Inovio Pharmaceuticals overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquart

Stocks similar to Inovio Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site